It was found that rosiglitazone, a PPARγ agonist, seriously increases hepatic steatosis, due to its elevated hepatic expression of PPARγ [51], while deleting PPARγ in liver cells protected mice against hepatic steatosis induced by high-fat diet [52]. The gene discussed is PPARG; the disease is fatty liver disease.